Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

The remarkably heterogeneous nature of lung cancer has become more apparent over the
last decade. In general, advanced lung cancer is an aggressive malignancy with a poor …

Context The analysis of molecular biomarkers in lung adenocarcinoma (ACA) is now a
central component of pathologic diagnosis and oncologic care. The identification of an …

Non-small cell lung cancer (NSCLC) is frequently associated with oncogenic driver
mutations, which play an important role in carcinogenesis and cancer progression …

EGFR gene mutations and ALK gene fusions are well‐characterized molecular targets in
NSCLC. Activating alterations in a variety of potential oncogenic driver genes have also …

The identification of oncogenic driver mutations underlying sensitivity to epidermal growth
factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge …

Although lung cancer remains the leading cancer killer in the United States, recently a
number of developments indicate future clinical benefit. These include evidence that …

Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …

The advent of novel therapeutics that specifically target signaling pathways activated by
genetic alterations has revolutionized the way patients with lung cancer are treated …

Lung cancers are characterised by abundant genetic diversity with relatively few recurrent
mutations occurring at high frequency. However, the genetic alterations often affect a …